PMID- 34766565
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 45
DP  - 2021 Nov 12
TI  - Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, 
      and cortisol levels in elderly patients with diabetes mellitus: A retrospective 
      study of a patient cohort.
PG  - e27638
LID - 10.1097/MD.0000000000027638 [doi]
LID - e27638
AB  - Adrenocorticotropic hormone (ACTH) and cortisol reportedly play a role in 
      glycemic control in patients with type 2 diabetes mellitus (T2DM); however, the 
      underlying mechanism remains controversial. We retrospectively investigated the 
      effect of tofogliflozin on serum ACTH and cortisol levels in elderly patients 
      with T2DM.Patients received 20 mg tofogliflozin daily for 3 months. Serum ACTH 
      and cortisol levels were measured at baseline, as well as after 1 month and 3 
      months of tofogliflozin therapy.Serum ACTH levels were significantly reduced 
      3 months after tofogliflozin treatment (P < .01). Additionally, serum cortisol 
      levels were reduced 3 months after tofogliflozin treatment, demonstrating 
      borderline significance (P = .05). The higher body mass index (BMI; >/=25 kg/m2) 
      group showed higher ACTH and cortisol levels than the lower BMI (<25 kg/m2) 
      group, with borderline significance (P = .05). Renin levels were significantly 
      increased 1 month after treatment (P < .05), maintaining serum aldosterone levels 
      in parallel with the extracellular fluid.Our findings suggested that 
      tofogliflozin decreased both serum ACTH and cortisol levels, with higher levels 
      observed in the high BMI group. Tofogliflozin increased serum renin levels while 
      maintaining serum aldosterone and extracellular fluid levels. Collectively, 
      tofogliflozin could affect the hypothalamic-pituitary-adrenal pathway in patients 
      with T2DM, especially in the low BMI group.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Higashikawa, Toshihiro
AU  - Higashikawa T
AUID- ORCID: 0000-0001-8690-5473
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
AD  - Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku-gun, Ishikawa, Japan.
FAU - Ito, Tomohiko
AU  - Ito T
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Mizuno, Takurou
AU  - Mizuno T
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Ishigami, Keiichirou
AU  - Ishigami K
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Kuroki, Kengo
AU  - Kuroki K
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Maekawa, Naoto
AU  - Maekawa N
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Usuda, Daisuke
AU  - Usuda D
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Morita, Takuro
AU  - Morita T
AD  - Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku-gun, Ishikawa, Japan.
FAU - Hamada, Kazu
AU  - Hamada K
AD  - Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku-gun, Ishikawa, Japan.
FAU - Takagi, Susumu
AU  - Takagi S
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Takeshima, Kento
AU  - Takeshima K
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Yamada, Shinya
AU  - Yamada S
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Sangen, Ryusho
AU  - Sangen R
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Izumida, Toshihide
AU  - Izumida T
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Mori, Hideyuki
AU  - Mori H
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Kiyosawa, Jun
AU  - Kiyosawa J
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Saito, Atsushi
AU  - Saito A
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Iguchi, Masaharu
AU  - Iguchi M
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Nakahashi, Takeshi
AU  - Nakahashi T
AD  - Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku-gun, Ishikawa, Japan.
FAU - Kasamaki, Yuji
AU  - Kasamaki Y
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Fukuda, Akihiro
AU  - Fukuda A
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Kanda, Tsugiyasu
AU  - Kanda T
AD  - Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, 
      Japan.
FAU - Okuro, Masashi
AU  - Okuro M
AD  - Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku-gun, Ishikawa, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 4964P6T9RB (Aldosterone)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - EC 3.4.23.15 (Renin)
RN  - P8DD8KX4O4 
      (6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adrenocorticotropic Hormone
MH  - Aged
MH  - *Aldosterone
MH  - Benzhydryl Compounds
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucosides
MH  - Humans
MH  - Hydrocortisone
MH  - Renin
MH  - Retrospective Studies
PMC - PMC8589243
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2021/11/13 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/11/12
CRDT- 2021/11/12 08:41
PHST- 2021/06/06 00:00 [received]
PHST- 2021/10/09 00:00 [accepted]
PHST- 2021/11/12 08:41 [entrez]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/11/12 00:00 [pmc-release]
AID - 00005792-202111120-00010 [pii]
AID - MD-D-21-04114 [pii]
AID - 10.1097/MD.0000000000027638 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Nov 12;100(45):e27638. doi: 
      10.1097/MD.0000000000027638.